Table 5: SEREX clones which encode ZRF1 (DNAJC2, MPP11) antigen.

Clone nameSourceFrequency of antibody response in cancer patients sera versus healthy donors seraPublication

NY-SCLC-6NCI-H740 and SK-LC-13 cell linesN/AGüre et al., PNAS, 2000; 97: 4198–4203 [19]
NY-BR-13Breast cancer3/10 BC versus 3/12 HDScanlan et al., Cancer Immun 2001: 4–21 [20]. (Ludwig-sun5.unil.ch/CancerImmunomeDB/)
NGO-St-58, 5Stomach cancer4/13 SC versus 3/16 HDObata et al.   (Ludwig-sun5.unil.ch/CancerImmunomeDB/) [21]
UL-CML-1K562 cell line from CML patient7/19 AML, 6/16 CML, 4/10 RCC, 3/6 MM, 3/12 BC, 3/10 OC versus 0/20 HDGreiner et al., Int. J. Cancer 2003; 106: 224–231 [22].
KY-MBC 29-88-1Breast cancer33/120 BC (including 1/10 MBC, 27/87 IDC, 5/23 ILC), 3/22 FA versus 2/50 HDPresent paper

BC: breast cancer patients; HD: healthy donors; SC: stomach cancer; RCC: renal cell carcinoma; MM: metastatic melanoma; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; OC: ovarian carcinoma.